SAN DIEGO, CA – November 18, 2024 – Antharis Therapeutics, a biopharmaceutical company advancing cutting-edge immunotherapeutic treatments in oncology, is pleased to announce that Patric Nelson, MBA, has officially joined the company as Chief Business Officer. Mr. Nelson brings extensive experience in business development, alliance management, and strategic partnerships, and will focus on driving the company’s business development initiatives and forming impactful partnerships to support the growth of Antharis’ innovative cancer therapies.
“I am delighted to welcome Patric to Antharis’ leadership team,” said Dr. Raphael Ribeiro-Pinaud, CEO and Chairman of Antharis Therapeutics. “His exceptional track record in strategic partnerships, transactions and business growth in the healthcare and biotechnology sectors make him an ideal leader to help us expand Antharis’ reach and impact. Patric’s expertise will play a vital role in our company’s strategy as we advance our mission of delivering transformative therapies to cancer patients.”
Mr. Nelson joins Antharis from Viracta, where he served as Senior Vice President of Business Development and Corporate Strategy. Before his tenure at Viracta, he was Vice President of Business Development and Alliance Management at Esperion Therapeutics, where he oversaw global business development efforts, securing over $2 billion in licensing transactions. His efforts helped establish Esperion’s alliance management function, fostering critical partnerships with global players Daiichi Sankyo and Otsuka. Mr. Nelson has also held positions at Amgen, Amylin Pharmaceuticals (acquired by AstraZeneca), Allergan (acquired by Abbvie), and Ionis, contributing to the development of successful therapies including Byetta®, Symlin®, Restasis®, Tegsedi®, and Repatha®.
“I am excited to be joining Antharis, an incredibly dynamic company, at such a critical stage of its growth, and contribute to its mission of pioneering impactful therapies in oncology”, said Mr. Nelson. “Antharis’ dedication to innovation and relentless focus on delivering next-generation therapies to patients with significant unmet medical needs aligns perfectly with my own values and expertise. I look forward to partnering with Raphael and the team in bringing Antharis' novel therapies to patients worldwide.”
Mr. Nelson holds an MPH in Public Health from the University of Southern California’s Keck School of Medicine and an MBA with distinction from USC’s Marshall School of Business.
About Antharis Therapeutics
Antharis Therapeutics is a leading biopharmaceutical company focused on developing innovative monoclonal antibody therapies for oncology and other critical medical fields. The company’s unique approach to cancer treatment leverages the power of immuno-oncology, enhancing the body’s immune response to fight cancer. With a robust pipeline of therapies and a multidisciplinary team of experts, Antharis is dedicated to transforming the future of healthcare by delivering safe, effective, and life-changing treatments to patients worldwide. For more information, please visit www.antharistherapeutics.com.
